Paper · 640238

Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects.

Ross SA and 1 other. Diabetes, 1978. Cited by 108 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects. Papers, record 640238. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/640238

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects.; PubMed
Journal: Diabetes; PubMed
Year: 1978; PubMed
Publication types: Comparative Study, Journal Article; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/640238/; PubMed
DOI: https://doi.org/10.2337/diab.27.3.327; PubMed
The journal: https://conductscience.org/library/journal-index/0372763; PubMed
Citations, by iCite: 108; iCite
Relative citation ratio, by iCite: 2.58; iCite
Revised in PubMed: 2019-05-15; PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	Kind	ORCID iD
1	Ross SA	S A
2	Dupre J	J

Source PubMed

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Diabetes Mellitus	Major topic
Galactose	Major topic
Gastric Inhibitory Polypeptide	Major topic
Gastrointestinal Hormones	Major topic
Glucose	Major topic
Triglycerides	Major topic
Administration, Oral
Adolescent
Adult
Blood Glucose
Glucagon
Humans
Insulin
Middle Aged

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by34

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 108 citations.

PMID	Title	Journal	Year	In Papers	Source
41,155,633	Thermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies.	Pharmaceuticals (Basel)	2025	https://conductscience.org/library/papers/41155633	PubMed
39,139,038	Incretin-based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future.	Med Res Rev	2025	https://conductscience.org/library/papers/39139038	PubMed
37,526,853	Beyond glycemia: Comparing tirzepatide to GLP-1 analogues.	Rev Endocr Metab Disord	2023	https://conductscience.org/library/papers/37526853	PubMed
32,500,274	GLP-1 Analogues as a Complementary Therapy in Patients after Metabolic Surgery: a Systematic Review and Qualitative Synthesis.	Obes Surg	2020	https://conductscience.org/library/papers/32500274	PubMed
31,392,745	Incretins in obesity and diabetes.	Ann N Y Acad Sci	2020	https://conductscience.org/library/papers/31392745	PubMed
28,223,856	Uncertainties around incretin-based therapies: A literature review.	Saudi Pharm J	2017	https://conductscience.org/library/papers/28223856	PubMed
26,557,956	New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders.	World J Diabetes	2015	https://conductscience.org/library/papers/26557956	PubMed
25,268,051	RNA-Seq analysis of enteroendocrine cells reveals a role for FABP5 in the control of GIP secretion.	Mol Endocrinol	2014	https://conductscience.org/library/papers/25268051	PubMed
25,047,836	A naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity.	Mol Cell Biol	2014	https://conductscience.org/library/papers/25047836	PubMed
23,736,366	Glucose-dependent insulinotropic polypeptide has impaired effect on abdominal, subcutaneous adipose tissue metabolism in obese subjects.	Int J Obes (Lond)	2014	https://conductscience.org/library/papers/23736366	PubMed

1 to 10 of 34

See all 34 cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
GCG	2,641	PubTator's text mining	https://conductscience.org/library/genes/2641	NCBI Gene
GIP	2,695	PubTator's text mining	https://conductscience.org/library/genes/2695	NCBI Gene
INS	3,630	PubTator's text mining	https://conductscience.org/library/genes/3630	NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/640238

GET https://conductscience.org/api/papers/v1/640238/cited_by?page=2

API reference For AI assistants